跳至主要内容
临床试验/JPRN-UMIN000046909
JPRN-UMIN000046909招募中未知

Impact of chronic endometritis in endometrial receptivity and the prediction of the personalized window of implantation: a prospective before-and-after study - Impact of chronic endometritis in the prediction of the personalized window of implantation: a prospective before-and-after study

Igenomix Foundation0 个研究点目标入组 240 人开始时间: 2022年2月15日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18years-old 至 37years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • Patients who are IUD carriers in the 3 months prior to the first biopsy for EMMA test. Patients who have taken prescribed antibiotics in the last 3 months prior to the first biopsy for EMMA test. Cases where the patient has received previous prophylactic antibiotics (1 single dose) to ovarian puncture in the stimulation cycle may be accepted. The administration of this prophylactic antibiotic should be at least 1 month before the sample collection (first biopsy for the EMMA test). Patients that received any surgical procedure in the 3 months prior to the first biopsy for EMMA test. Patients that present a different endometrial preparation (HRT) for the different cycles included in the study (1st mock cycle, 2nd mock cycle, ET cycle) in terms of P4 dosage, timing or route of administration. Patients with endogenous P4 >1ng/mL determined at day P+0 of the HRT cycles included in the study (1st mock cycle, 2nd mock cycle, ET cycle) or with unknow levels of endogenous P4 before the administration exogenous progesterone in any of the HRT cycles included in the study. Patients receiving personalized ET with embryos other than blastocyst in days 5 or 6. Patients cured of CE that do not follow the recommendations of the 2nd ERA test for pET. And others.

研究者

发起方
Igenomix Foundation

相似试验